Global Cardiovascular Risk in Patients with HIV Infection: Concordance and Differences in Estimates According to Three Risk Equations (Framingham, SCORE, and PROCAM)
- 1 July 2007
- journal article
- Published by Mary Ann Liebert Inc in AIDS Patient Care and STDs
- Vol. 21 (7) , 452-457
- https://doi.org/10.1089/apc.2006.0165
Abstract
To compare cardiovascular risk stratification according to Framingham, PROCAM (Prospective Cardiovascular Münster), and SCORE (Systematic Coronary Risk Evaluation) equations in patients with HIV infection, a cross-sectional study of a well-characterized cohort of 760 HIV-infected adults managed at the outpatient Infectious Disease Unit in 2003 was conducted. Cardiovascular risk score was examined and patients were classified as having low, moderate, or high risk using Framingham and PROCAM (/=5%, respectively) equations. The prevalence of patients with low, moderate and high cardiovascular risk was 76.6%, 15.1%, and 8.3% by the Framingham, respectively, 90.1%, 4.9%, and 5% by the PROCAM, respectively, and 88.6%, 3%, and 8.4% by SCORE, respectively. Concordance between these three risk functions was significant, but globally moderate (Framingham and PROCAM, kappa 0.36, p < 0.0001; Framingham and SCORE, kappa 0.32, p < 0.0001; PROCAM and SCORE, kappa 0.46, p < 0.0001). The Framingham equation categorized a higher proportion of HIV-infected male patients with moderate cardiovascular risk and a lower proportion of those with low risk (p < 0.0001) compared with PROCAM and SCORE. The present study showed a high prevalence of HIV-infected patients at low cardiovascular risk regardless of the assessed coronary risk system used. However, compared with PROCAM and SCORE, Framingham risk equation in HIV-infected patients identified a higher number of male patients with moderate cardiovascular risk.Keywords
This publication has 24 references indexed in Scilit:
- Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected AdultsNew England Journal of Medicine, 2005
- Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials GroupClinical Infectious Diseases, 2003
- The Pavia consensus statementAIDS, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chartHeart, 2000
- Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population studyEuropean Heart Journal, 2000
- Prediction of Coronary Heart Disease Using Risk Factor CategoriesCirculation, 1998
- Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield tableThe Lancet, 1996
- Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart diseaseThe Lancet, 1995
- An updated coronary risk profile. A statement for health professionals.Circulation, 1991